牛牛AI助理已提取核心讯息新锐医药国际控股有限公司公布截至2025年6月30日止六个月业绩。期内总收入约4,470万港元,较去年同期的1,672万港元大幅增长167.4%。收入增长主要由于集团自2024年下半年起于中国推出新医药产品,但部分被主要产品二代头孢产品需求下跌所抵销。尽管收入增加,但期内净亏损扩大至约745万港元,较去年同期的409万港元增加82.3%。亏损扩大主要由于新产品尚处于起步...
Source Link牛牛AI助理已提取核心讯息新锐医药国际控股有限公司公布截至2025年6月30日止六个月业绩。期内总收入约4,470万港元,较去年同期的1,672万港元大幅增长167.4%。收入增长主要由于集团自2024年下半年起于中国推出新医药产品,但部分被主要产品二代头孢产品需求下跌所抵销。尽管收入增加,但期内净亏损扩大至约745万港元,较去年同期的409万港元增加82.3%。亏损扩大主要由于新产品尚处于起步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.